



## **eureKARE announces prestigious roundtable for inaugural SynBio Day**

- ***Roundtable discussion speakers announced***
- ***Free virtual event on 10 November 2021; delegates required to register [here](#)***
- ***eureKAWARDS winner will be announced at the event***

**Luxembourg and Paris, France – 28 October 2021:** eureKARE ("the Company"), a pioneering new company focused on financing and building next generation biotechnology companies in the disruptive fields of synthetic biology and the microbiome, today announces details of its roundtable discussion at its inaugural ***eureKARE SynBio Day***, taking place on November 10<sup>th</sup>, 2021. As part of promoting innovation in synthetic biology, eureKARE is hosting this event which aims to bring together stakeholders from across the synthetic biology industry, including investors, academic researchers, and other key industry players.

The discussion, titled '*Major challenges in synthetic biology for today and tomorrow*' features highly esteemed speakers from the synthetic biology field. Participants will include:

- Anya Roy, Head of Illumina Accelerator UK
- Ana Atanassova, Global Regulatory Policy, BASF AP
- Prof. Darian Meacham, Maastricht University
- Dr. Rodrigo Ledesma Amaro, Team Leader, Imperial College London
- Fiona Mischel, Editor in Chief, Synbiobeta
- Dr. Yuval Dorfan, IDC, Israeli SynBio Institute founding director
- Dr. Karen Fallen, CEO, Touchlight

The roundtable discussion will be moderated by Nastassia Astrasheuskaya, Financial Times correspondent covering energy, mining, Russia and Central Asia.

The first SynBio Day event will be comprised of presentations from leaders in synthetic biology across Europe, the roundtable discussion, networking, the eureKAWARDS finalists' pitches and announcement of the winner as judged by a jury of highly esteemed experts in the synthetic biology field.

Registration to attend the eureKARE SynBio Day event virtually is open, [here](#).

**- End -**

### **About eureKARE**

eureKARE is a unique project development company dedicated to investing and developing next generation biotechnology companies in the cutting-edge fields of the microbiome and synthetic

biology. eureKARE has a two-step investment approach to deliver long-term value creation. The Company supports translational research by creating and financing new companies out of high value European science through its biotech start-up studios eureKABIOME (Microbiome) and eureKASYNBIO (Synthetic biology). The Company also intends to invest in more mature biotech companies and will systematically propose to offer some liquidity to early investors, thereby addressing a critical need in the European biotech field. Guided by its influential founder, Alexandre Mouradian, and a pan-European team, eureKARE has a rapidly growing portfolio of companies that have the potential to disrupt the life sciences industry.

**For more information**

**eureKARE SA**

Marina Shapochnik, Head Investor Relations  
[marina.shapochnik@eurekare.eu](mailto:marina.shapochnik@eurekare.eu)

**Consilium Strategic Communications**

Amber Fennell, Sukaina Virji, Genevieve Wilson  
+44 (0) 203 709 5000  
[eurekare@consilium-comms.com](mailto:eurekare@consilium-comms.com)